The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Mar 3, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor, is looking at how certain genetic markers in tumor tissue can help doctors understand the behavior of urothelial tumors, which are a type of cancer affecting the urinary tract. The goal is to find specific genetic profiles that can predict how the cancer will progress and whether it will respond to various treatments. By identifying these markers, the study hopes to improve treatment plans for patients with advanced stages of this cancer.
To participate in this trial, you need to be at least 18 years old and have been diagnosed with either locally advanced or metastatic urothelial cancer. You should also have tumor tissue available from a recent surgery or biopsy. If you choose to take part, you'll need to give your written consent to join the study. The trial is currently recruiting participants, and everyone involved will be helping to advance our understanding of this disease and potentially improve future treatments for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria For the retrospective part:
- • - Patients diagnosed with locally advanced operated or metastatic urothelial cancer in follow-up or treatment
- Exclusion Criteria For the retrospective part:
- • - Deceased patients who have not already performed the NGS analysis from clinical practice.
- For the prospective part:
- • Patients
- • aged \> 18 years
- • suffering from locally advanced or metastatic urothelial neoplasia
- • with the availability of tumor tissue obtained during surgery on a primary tumor or metastasis or during a diagnostic biopsy.
- • Patients included in the study will also have to consciously express their willingness to participate in the study after signing the written informed consent.
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Francesco Massari, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported